Clinical Efficacy and Safety of Ivacaftor/Lumacaftor Combination in Patients with Cystic Fibrosis: International Studies Review

Cystic fibrosis is an autosomal recessive disease caused by structure abnormalities in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. It is characterized by severe course and poor prognosis without or with insufficient treatment. Approval of pathogenetic therapy medications, CF...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Nataliya Yu. Kashirskaya, Nika V. Petrova, Rena A. Zinchenko
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	"Paediatrician" Publishers LLC 2021-12-01
Edice:	Вопросы современной педиатрии
Témata:	cystic fibrosis pathogenetic therapy cftr modulators ivacaftor lumacaftor
On-line přístup:	https://vsp.spr-journal.ru/jour/article/view/2794
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!